IMMUNOe Research Centers
Assessment of RUCONEST (C1 Esterase Inhibitor \[Recombinant\]) in Alleviating Neurological Symptoms Linked to Infectious Pathogens
This study will last approximately 30 weeks including 24 infusions total, each one week apart. This is an open label extension study aimed to investigate the continued use of RUCONEST in a post-SARS-CoV-2 population who experienced neurological symptoms both in patients who have participated in the previous trial (NCT04705831) as well as RUCONEST-naive participants.
Inclusion Criteria: * Age 18 and older, male or female * Patient is able to understand and fully participate in the activities of the study and the consent in accordance with federal regulations. * Patients who were involved in the previous study with defined post-COVID neurologic symptoms. * New patients who have been diagnosed with post-COVID neurologic symptoms. Exclusion Criteria: * Receiving any form of C1-INH therapy, either acute or prophylactic treatment * History or suspicion of allergy to rabbits * Neurological conditions related to injury * Neuropathy related to diabetes * Abnorm…
IV Ruconest
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.